Concr
Precision diagnostics for cancer treatment
- 1-20 employees
- B2B
- Deep Tech
- Machine Learning
- MedTech
- Westminster, London, UK
Jump to section
Company mission
To unlock data's complexity and realise the promise of precision oncology.
Our take
Despite improving research, over 90% of novel cancer drugs fail early in clinical trials. Concr is a biotech company that is pioneering a new approach to precision oncology, with its statistical learning-powered biomarker prediction engine. This uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies.
Concr's platform enables users to store, manage and analyse all data from one place, easily generating meaningful actionable insights for cost-effective drug development and patient treatment. Its proprietary data modelling integrates disparate data and tests from across the pipeline and different indications, overall making actionable predictions using 300x less pre-clinical and 7x less clinical data.
The company closed a seed funding round in 2023, which has been used to enhance its scientific and product development and grow its portfolio of pharmaceutical partnerships. Now, the company is well placed to see continued growth, as its biomarker prediction engine is set to deliver lifesaving insights to patients around the globe.
Freddie
Company Specialist at Welcome to the Jungle
Funding (last 2 of 4 rounds)
May 2023
$1.7m
SEED
May 2022
$1.7m
SEED
Total funding: $4m
Leadership
Matthew Foster
(Co-Founder)Former Graduate Student in Biomedical Engineering, Associate Researcher at Imperial College London, and Biological Engineering Founder at Deep Science Ventures.
Matthew Griffiths
(Co-Founder)Former PhD student at the University of Cambridge and Founder of Deep Science Ventures.
Irina Babina
(CEO)Irina joined Concr in 2022 as Head of Strategy, becoming Chief Business Officer in 2023 and CEO in 2024.